Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries
As the economic burden of treating cancer patients has been soaring in European countries, performing a budget impact analysis is becoming one of the requirements for payers’ application dossiers.
The objective of this study was to estimate the budgetary impact of introducing the biosimilar trastuzumab (CT-P6) from the payer’s perspective and to determine the number of additional patients who could be treated with resulting savings in 28 European countries.
A budget impact model was developed to analyze the financial impact of switching from originator trastuzumab to biosimilar CT-P6 in the treatment of early and metastatic breast cancer and metastatic gastric cancer with a time horizon of 1–5 years. Budgetary savings and the number of patients potentially affected were measured based on epidemiological and sales volume data. The base-case analysis assumed that the price of CT-P6 is 70% of the originator price, the switching rate of originator to CT-P6 in the first year is 20%, and the annual growth in the switching rate for each subsequent year is 5%.
For analyses using the base-case scenario following CT-P6 introduction, the total estimated budgetary savings over a 5-year period (depending on the scenario) ranged from €1.13 billion to €2.27 billion based on epidemiological data, or from €0.91 billion to €1.82 billion based on sales volume data. In the first year only, the projected budgetary savings ranged from €58 million to €136 million, and the number of additional patients who could be treated using the savings ranged from 3503 to 7078 by sensitivity analysis.
The conducted budget impact analysis assessing a switch from originator trastuzumab to biosimilar CT-P6 in 28 European countries indicates that budget savings could be between €0.91 billion and €2.27 billion over the next 5 years. These savings could be used to help improve patient access to local biologics in their respective countries while simultaneously strengthening the overall public health landscape across the European Union.
The authors would like to thank Gil-Hwan Lew for the study design and data collection and analysis in the early stages of this study. Editorial support (which included editing and styling an advanced draft provided by the authors) was provided by Emma Evans PhD at Aspire Scientific (Bollington, UK).
S.-M. Lee and J.-H. Jung contributed equally to the study design, statistical analysis, and manuscript development under the guidance of D.-C. Suh. D. Suh, Y.-S. Jung, S.-L. Yoo, D.-W. Kim, and J.-A. Kim contributed to the acquisition, analysis, and interpretation of data and were involved in drafting and revising the manuscript. All authors have approved the submitted version to be published and agree to be accountable for aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The sponsor was not involved in the study design or in the analysis and interpretation of the data.
Compliance with Ethical Standards
This research was supported by the Chung-Ang University research grant in 2019. This study was partially funded by a research grant including editorial support from Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).
Conflict of Interest
S.-M. Lee, J.-H. Jung, D. Suh, Y.-S. Jung, S.-L. Yoo, D.-W. Kim, J.-A. Kim, and D.-C. Suh declare that they have no conflict of interest.
- 1.Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68. https://doi.org/10.1001/jamaoncol.2018.2706.CrossRefGoogle Scholar
- 4.F. Hoffmann-La Roche Ltd. Finance report 2018. Basel: F. Hoffmann-La Roche Ltd.; 2019.Google Scholar
- 8.Baji P, Pentek M, Szanto S, Geher P, Gulacsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014;15:S45–52. https://doi.org/10.1007/s10198-014-0593-5.CrossRefGoogle Scholar
- 9.Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases; a systematic review and meta-analysis. J Autoimmun. 2017;79:4–16. https://doi.org/10.1016/j.jaut.2017.02.003.CrossRefGoogle Scholar
- 10.Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–57. https://doi.org/10.1111/apt.13990.CrossRefGoogle Scholar
- 11.Cantini F, Benucci M. Focus on biosimilar etanercept - bioequivalence and interchangeability. Biologics. 2018;12:87–95.Google Scholar
- 14.Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–16.CrossRefGoogle Scholar
- 25.National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: breast cancer (version 2). 2017. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 15 Jun 2017.
- 29.Im YH, Odarchenko P, Grecea D, Komov D, Anatoliy CV, Gupta S, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol. 2013;31(15).Google Scholar
- 30.Stebbing J, Baranau Y, Baryash V. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017). Lancet Oncol. 2017;18(9):E510-E.Google Scholar
- 31.Stebbing J, Valerievich Y, Baryash BV, Manikhas A, Moiseyenko V, Dzagnidze G, et al. Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC) [abstract]. J Clin Oncol. 2017;35(15 Suppl):510. https://doi.org/10.1200/JCO.2017.35.15_suppl.510.CrossRefGoogle Scholar
- 34.Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. https://doi.org/10.1016/j.jval.2013.08.2291.CrossRefGoogle Scholar
- 38.Chalkidou K, Marquez P, Dhillon P, Teerawattananon Y, Anothaisintawee T, Gadelha CA, et al. Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol. 2014;15(3):e119-31. https://doi.org/10.1016/S1470-2045(13)70547-3.CrossRefGoogle Scholar
- 40.Cancer Research UK. Statistics by cancer type. 2017. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type. Accessed 15 Sep 2018.
- 41.The World Bank. Population. 2017. http://data.worldbank.org/indicator/SP.POP.TOTL. Accessed 15 Sep 2018.
- 42.Walpole SC, Prieto-Merion D, Edwards P, Cleland J, Stevens G, Roberts L. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012;12:439. https://doi.org/http://www.biomedcentral.com/1471-2458/12/439.
- 45.European Commission. European Cancer Information System. 2017. https://ecis.jrc.ec.europa.eu/. Accessed 10 Aug 2018.
- 51.Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.Google Scholar
- 54.Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat. 2010;119(1):127–36. https://doi.org/10.1007/s10549-009-0498-7.CrossRefGoogle Scholar
- 55.Lang I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, et al. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial. Clin Oncol (R Coll Radiol). 2014;26(2):81–9. https://doi.org/10.1016/j.clon.2013.08.011.CrossRefGoogle Scholar
- 56.Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.CrossRefGoogle Scholar
- 59.Severs M, Oldenburg B, van Bodegraven A, Siersema P, Mangen M. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289–96.Google Scholar
- 66.European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Accessed 10 Mar 2018.
- 73.Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous trastuzumab (Herceptin): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res. 2013;2:133–40.CrossRefGoogle Scholar
- 74.Tjalma WAA, Van de Mooter T, Mertens T, Bastiaens V, Huizing MT, Papadimitriou K. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46–51.CrossRefGoogle Scholar